Pfizer Partner to Seek Approval Soon for Vaccine for 5- to 11-Year-Olds: Executives

BioNTech, which developed one of the world’s most commonly used COVID-19 vaccines along with Pfizer, is attempting to gain approval soon for vaccinating children between the ages of 5 and 11 across the world, top executives with the firm announced Friday.

“Already over the next few weeks we will file the results of our trial in 5- to 11-year-olds with regulators across the world and will request approval of the vaccine in this age group, also here